iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. announce collaborative agreement to offer a combined service offering
iThemba Pharmaceuticals’ service division and Pyxis Discovery announced that they have signed a collaborative agreement to jointly market both companies’ services.
Pyxis’s computational chemistry and lead discovery expertise will be coupled with iThemba’s service division to provide medicinal and synthetic chemistry support to projects identified through Pyxis’ international client network. iThemba Pharmaceuticals and Pyxis Discovery also announced that they are entering into a co-marketing agreement to offer virtual libraries which will be exclusively synthesized for clients. Pyxis’s smart approach of designing and selecting compounds facilitates a rapid and efficient lead discovery and library design process and this coupled to iThemba’s expertise in synthetic and medicinal chemistry will provide our customers with a unique service offering opportunity.
“The intellectual and technological support from Pyxis will enhance both of our service offerings” said Chris Edlin, CSO of iThemba. “Our customers will gain the advantage of our coupled expertise in design, synthesis and medicinal chemistry prowess”.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
